BIONOMICS TO PRESENT ALZHEIMER’S DRUG CANDIDATE AT US NEUROSCIENCE CONFERENCES

Bionomics Limited (ASX:BNO, ADR:BMICY) will present a poster on BNC375, its lead Alzheimer’s disease drug candidate, at the Neuroscience 2013 conference and nAChR2013 satellite symposium, both being held by the Society of Neuroscience (SFN) in San Diego this month.

The nAChR2013 satellite symposium, Nicotinic Acetylcholine Receptors (nAChR) as Therapeutic Targets: Emerging Frontiers in Basic Research & Clinical Science, is a biennial event to be held this year on 6-8 November. It follows the success of the past three satellite symposium events in bringing together the top researchers in basic science and clinical research to analyse developments and strategy in nAChR biology.

Neuroscience 2013 will be the 43rd annual meeting for the SFN and expects to bring together 30,000 experts from over 80 countries over 9-13 November. It is the world’s largest conference dedicated to neuroscience and enables peers in the industry to forge collaborations, explore new technologies and advance therapy development.

Bionomics will present on the “Characterization of BNC375, a novel α7 nAChR positive allosteric modulator for the treatment of cognitive impairment in Alzheimer’s disease”.

BNC375 has shown potent efficacy in animal cognitive impairment models and has the potential to be effective against a range of disease states from mild to severe. In the animal models BNC375 is benchmarked against Donepezil (Aricept). Aricept, first approved in 1996, is the largest selling drug for treatment of cognitive deficit in Alzheimer’s disease.

SFN is the world’s largest organisation of scientists and physicians devoted to the study of the brain and nervous system. Founded in 1969 it has over 40,000 members with 130 chapters across the world.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 / 0418 160 425
drathjen@bionomics.com.au

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group
Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com
About Bionomics Limited

Bionomics (ASX: BNO) is an Australian based international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule and antibody product development programs in the areas of cancer, anxiety, and memory loss. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

BNC105, which is undergoing Phase II clinical development in a range of solid tumour types, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. BNC105 offers blockbuster potential if successfully developed. A clinical program is also underway for the treatment of anxiety disorders and depression based on IW-2143(BNC210), a novel compound which stimulates neurite outgrowth. IW-2143 is partnered with Ironwood Pharmaceuticals.

Bionomics’ discovery and development activities are driven by its four proprietary technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX®, a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics’ pipeline and underpin its established business strategy of securing partners for its key compounds.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains “forward-looking” statements within the meaning of the United States’ Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics’ development candidates BNC105, IW-2143 (BNC210), BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deals with Ironwood Pharmaceuticals and Merck, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers’ markets, our failure to introduce new products or technologies in a timely manner, Ironwood’s decisions to continue or not continue development of IW-2143, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.